

ISSN 2518-1467 (Online),  
ISSN 1991-3494 (Print)

ҚАЗАҚСТАН РЕСПУБЛИКАСЫ  
ҰЛТТЫҚ ҒЫЛЫМ АКАДЕМИЯСЫНЫҢ

# Х А Б А Р Ш Ы С Ы

---

---

**ВЕСТНИК**

НАЦИОНАЛЬНОЙ АКАДЕМИИ НАУК  
РЕСПУБЛИКИ КАЗАХСТАН

**THE BULLETIN**

THE NATIONAL ACADEMY OF SCIENCES  
OF THE REPUBLIC OF KAZAKHSTAN

PUBLISHED SINCE 1944

5

SEPTEMBER – OCTOBER 2019

---

---

ALMATY, NAS RK

---

---

*NAS RK is pleased to announce that Bulletin of NAS RK scientific journal has been accepted for indexing in the Emerging Sources Citation Index, a new edition of Web of Science. Content in this index is under consideration by Clarivate Analytics to be accepted in the Science Citation Index Expanded, the Social Sciences Citation Index, and the Arts & Humanities Citation Index. The quality and depth of content Web of Science offers to researchers, authors, publishers, and institutions sets it apart from other research databases. The inclusion of Bulletin of NAS RK in the Emerging Sources Citation Index demonstrates our dedication to providing the most relevant and influential multidiscipline content to our community.*

*Қазақстан Республикасы Ұлттық ғылым академиясы "ҚР ҰҒА Хабаршысы" ғылыми журналының Web of Science-тің жаңаланған нұсқасы Emerging Sources Citation Index-те индекстелуге қабылданғанын хабарлайды. Бұл индекстелу барысында Clarivate Analytics компаниясы журналды одан әрі the Science Citation Index Expanded, the Social Sciences Citation Index және the Arts & Humanities Citation Index-ке қабылдау мәселесін қарастыруда. Web of Science зерттеушілер, авторлар, баспашылар мен мекемелерге контент тереңдігі мен сапасын ұсынады. ҚР ҰҒА Хабаршысының Emerging Sources Citation Index-ке енуі біздің қоғамдастық үшін ең өзекті және беделді мультидисциплинарлы контентке адалдығымызды білдіреді.*

*НАН РК сообщает, что научный журнал «Вестник НАН РК» был принят для индексирования в Emerging Sources Citation Index, обновленной версии Web of Science. Содержание в этом индексировании находится в стадии рассмотрения компанией Clarivate Analytics для дальнейшего принятия журнала в the Science Citation Index Expanded, the Social Sciences Citation Index и the Arts & Humanities Citation Index. Web of Science предлагает качество и глубину контента для исследователей, авторов, издателей и учреждений. Включение Вестника НАН РК в Emerging Sources Citation Index демонстрирует нашу приверженность к наиболее актуальному и влиятельному мультидисциплинарному контенту для нашего сообщества.*

Б а с р е д а к т о р ы

х. ғ. д., проф., ҚР ҰҒА академигі

**М. Ж. Жұрынов**

Р е д а к ц и я а л қ а с ы:

**Абиев Р.Ш.** проф. (Ресей)  
**Абишев М.Е.** проф., корр.-мүшесі (Қазақстан)  
**Аврамов К.В.** проф. (Украина)  
**Аппель Юрген** проф. (Германия)  
**Баймуқанов Д.А.** проф., корр.-мүшесі (Қазақстан)  
**Байтулин И.О.** проф., академик (Қазақстан)  
**Банас Иозеф** проф. (Польша)  
**Берсимбаев Р.И.** проф., академик (Қазақстан)  
**Велесько С.** проф. (Германия)  
**Велихов Е.П.** проф., РҒА академигі (Ресей)  
**Гашимзаде Ф.** проф., академик (Әзірбайжан)  
**Гончарук В.В.** проф., академик (Украина)  
**Давлетов А.Е.** проф., корр.-мүшесі (Қазақстан)  
**Джрбашян Р.Т.** проф., академик (Армения)  
**Қалимолдаев М.Н.** проф., академик (Қазақстан), бас ред. орынбасары  
**Лаверов Н.П.** проф., академик РАН (Россия)  
**Лупашку Ф.** проф., корр.-мүшесі (Молдова)  
**Мохд Хасан Селамат** проф. (Малайзия)  
**Мырхалықов Ж.У.** проф., академик (Қазақстан)  
**Новак Изабелла** проф. (Польша)  
**Огарь Н.П.** проф., корр.-мүшесі (Қазақстан)  
**Полещук О.Х.** проф. (Ресей)  
**Поняев А.И.** проф. (Ресей)  
**Сагиян А.С.** проф., академик (Армения)  
**Сатубалдин С.С.** проф., академик (Қазақстан)  
**Таткеева Г.Г.** проф., корр.-мүшесі (Қазақстан)  
**Умбетаев И.** проф., академик (Қазақстан)  
**Хрипунов Г.С.** проф. (Украина)  
**Юлдашбаев Ю.А.** проф., РҒА корр.-мүшесі (Ресей)  
**Якубова М.М.** проф., академик (Тәжікстан)

«Қазақстан Республикасы Ұлттық ғылым академиясының Хабаршысы».

**ISSN 2518-1467 (Online),**

**ISSN 1991-3494 (Print)**

Меншіктенуші: «Қазақстан Республикасының Ұлттық ғылым академиясы»РҚБ (Алматы қ.)

Қазақстан республикасының Мәдениет пен ақпарат министрлігінің Ақпарат және мұрағат комитетінде  
01.06.2006 ж. берілген №5551-Ж мерзімдік басылым тіркеуіне қойылу туралы куәлік

Мерзімділігі: жылына 6 рет.

Тиражы: 2000 дана.

Редакцияның мекенжайы: 050010, Алматы қ., Шевченко көш., 28, 219 бөл., 220, тел.: 272-13-19, 272-13-18,  
<http://www.bulletin-science.kz/index.php/en/>

---

© Қазақстан Республикасының Ұлттық ғылым академиясы, 2019

Типографияның мекенжайы: «Аруна» ЖК, Алматы қ., Муратбаева көш., 75.

Г л а в н ы й р е д а к т о р  
д. х. н., проф. академик НАН РК  
**М. Ж. Журинов**

Р е д а к ц и о н н а я к о л л е г и я:

**Абиев Р.Ш.** проф. (Россия)  
**Абишев М.Е.** проф., член-корр. (Казахстан)  
**Аврамов К.В.** проф. (Украина)  
**Апель Юрген** проф. (Германия)  
**Баймуканов Д.А.** проф., чл.-корр. (Казахстан)  
**Байтулин И.О.** проф., академик (Казахстан)  
**Банас Иозеф** проф. (Польша)  
**Берсимбаев Р.И.** проф., академик (Казахстан)  
**Велесько С.** проф. (Германия)  
**Велихов Е.П.** проф., академик РАН (Россия)  
**Гашимзаде Ф.** проф., академик (Азербайджан)  
**Гончарук В.В.** проф., академик (Украина)  
**Давлетов А.Е.** проф., чл.-корр. (Казахстан)  
**Джрбашян Р.Т.** проф., академик (Армения)  
**Калимолдаев М.Н.** академик (Казахстан), зам. гл. ред.  
**Лаверов Н.П.** проф., академик РАН (Россия)  
**Лунашку Ф.** проф., чл.-корр. (Молдова)  
**Моход Хасан Селамат** проф. (Малайзия)  
**Мырхалыков Ж.У.** проф., академик (Казахстан)  
**Новак Изабелла** проф. (Польша)  
**Огарь Н.П.** проф., чл.-корр. (Казахстан)  
**Полещук О.Х.** проф. (Россия)  
**Поняев А.И.** проф. (Россия)  
**Сагьян А.С.** проф., академик (Армения)  
**Сатубалдин С.С.** проф., академик (Казахстан)  
**Таткеева Г.Г.** проф., чл.-корр. (Казахстан)  
**Умбетаев И.** проф., академик (Казахстан)  
**Хрипунов Г.С.** проф. (Украина)  
**Юлдашбаев Ю.А.** проф., член-корр. РАН (Россия)  
**Якубова М.М.** проф., академик (Таджикистан)

**«Вестник Национальной академии наук Республики Казахстан».**

**ISSN 2518-1467 (Online),**

**ISSN 1991-3494 (Print)**

Собственник: РОО «Национальная академия наук Республики Казахстан» (г. Алматы)

Свидетельство о постановке на учет периодического печатного издания в Комитете информации и архивов Министерства культуры и информации Республики Казахстан №5551-Ж, выданное 01.06.2006 г.

Периодичность: 6 раз в год

Тираж: 2000 экземпляров

Адрес редакции: 050010, г. Алматы, ул. Шевченко, 28, ком. 219, 220, тел. 272-13-19, 272-13-18.

www: nauka-nanrk.kz, bulletin-science.kz

---

© Национальная академия наук Республики Казахстан, 2019

Адрес типографии: ИП «Аруна», г. Алматы, ул. Муратбаева, 75

E d i t o r i n c h i e f

doctor of chemistry, professor, academician of NAS RK

**M. Zh. Zhurinov**

E d i t o r i a l b o a r d:

**Abiyev R.Sh.** prof. (Russia)  
**Abishev M.Ye.** prof., corr. member. (Kazakhstan)  
**Avramov K.V.** prof. (Ukraine)  
**Appel Jurgen,** prof. (Germany)  
**Baimukanov D.A.** prof., corr. member. (Kazakhstan)  
**Baitullin I.O.** prof., academician (Kazakhstan)  
**Joseph Banas,** prof. (Poland)  
**Bersimbayev R.I.** prof., academician (Kazakhstan)  
**Velesco S.,** prof. (Germany)  
**Velikhov Ye.P.** prof., academician of RAS (Russia)  
**Gashimzade F.** prof., academician (Azerbaijan)  
**Goncharuk V.V.** prof., academician (Ukraine)  
**Davletov A.Ye.** prof., corr. member. (Kazakhstan)  
**Dzhrbashian R.T.** prof., academician (Armenia)  
**Kalimoldayev M.N.** prof., academician (Kazakhstan), deputy editor in chief  
**Laverov N.P.** prof., academician of RAS (Russia)  
**Lupashku F.** prof., corr. member. (Moldova)  
**Mohd Hassan Selamat,** prof. (Malaysia)  
**Myrkhalykov Zh.U.** prof., academician (Kazakhstan)  
**Nowak Isabella,** prof. (Poland)  
**Ogar N.P.** prof., corr. member. (Kazakhstan)  
**Poleshchuk O.Kh.** prof. (Russia)  
**Ponyaev A.I.** prof. (Russia)  
**Sagiyani A.S.** prof., academician (Armenia)  
**Satubaldin S.S.** prof., academician (Kazakhstan)  
**Tatkeyeva G.G.** prof., corr. member. (Kazakhstan)  
**Umbetayev I.** prof., academician (Kazakhstan)  
**Khripunov G.S.** prof. (Ukraine)  
**Yuldashbayev Y.A.,** prof. corresponding member of RAS (Russia)  
**Yakubova M.M.** prof., academician (Tadjikistan)

**Bulletin of the National Academy of Sciences of the Republic of Kazakhstan.**

**ISSN 2518-1467 (Online),**

**ISSN 1991-3494 (Print)**

Owner: RPA "National Academy of Sciences of the Republic of Kazakhstan" (Almaty)

The certificate of registration of a periodic printed publication in the Committee of Information and Archives of the Ministry of Culture and Information of the Republic of Kazakhstan N 5551-Ж, issued 01.06.2006

Periodicity: 6 times a year

Circulation: 2000 copies

Editorial address: 28, Shevchenko str., of. 219, 220, Almaty, 050010, tel. 272-13-19, 272-13-18,  
<http://nauka-nanrk.kz/>, <http://bulletin-science.kz>

---

© National Academy of Sciences of the Republic of Kazakhstan, 2019

Address of printing house: ST "Aruna", 75, Muratbayev str, Almaty

UDC 616-006.6

V. V. Benberin<sup>1</sup>, N. A. Shanazarov<sup>1</sup>, N. K. Seidalin<sup>1</sup>,  
N. Y. Lisovska<sup>2</sup>, T. A. Vochshenkova<sup>1</sup>, G. A. Yermakhanova<sup>1</sup>

<sup>1</sup>Medical Center Hospital of President's Affairs Administration of the Republic of Kazakhstan, Astana, Kazakhstan,

<sup>2</sup>Center of Oncology 'Clinic of Spizhenko', Kiev region, Ukraine.

E-mail: valeriy-benberin@mail.ru, nasrulla@inbox.ru, nkseidalin@mail.ru, lisovska67@gmail.com,  
vochshenkova@gmail.com, ermakhanova@gmail.com

## CLINICAL IMPORTANCE OF DEFINITION OF SINGLE NUCLEOTIC POLYMORPHISMS IN PATIENTS WITH BREAST CANCER (LITERATURE REVIEW)

**Abstract.** Purpose of the review: The study of literature data relating to the replacement of nucleotides in DNA with the risk of development, course and prognosis of breast cancer.

Materials and methods. A literature review was conducted in electronic databases included in PubMed/Medline, The Cochrane Library. The depth of search was 10 years.

Results. The data on the role of single nucleotide polymorphisms in the development, course, prognosis and response to treatment for breast cancer in individual populations was studied. The research results show that the replacement of nucleotides in DNA underlies the differences in susceptibility to the development of diseases, the effectiveness of the action of medicines.

Conclusion. The determination of single nucleotide polymorphisms can reveal a hereditary predisposition to various multifactorial diseases (including cancer), and to predict individual sensitivity to pharmacological medicines. This can help physicians choose the most effective treatment for breast cancer patients.

**Keywords:** breast cancer, single nucleotide polymorphism, prognosis of the course, risk of development.

**Introduction.** Breast cancer affects up to 12% of women worldwide. According to statistics, in the United States, in 2015, nearly 3 million cases of breast cancer were registered [1]. Risk factors for breast cancer include lifestyle, other pathological conditions, and genetic predisposition [2]. Epidemiological studies show that women with a family history of breast cancer have a higher risk of developing than those who do not have it [3].

Numerous recent studies have reported on the association between single nucleotide polymorphisms (SNP) in genes and the risk of developing breast cancer. Determining the interactions of genetic factors and environmental risk factors has the potential to understand the processes leading to the development of the disease, identify women for whom these risk factors are most relevant, and improve the accuracy of epidemiological risk models.

SNP is a variation of the DNA sequence that occurs when one nucleotide (A, T, C, or G) in the genome is different from the normally expected nucleotide. These SNPs are known to be at the core of the differences in our susceptibility to developing diseases. The definition of SNP is technically not difficult and is carried out only once, which makes them relevant in quality of use as biomarkers. The number of SNPs in the human genome is about 10 million. Their changes can lead to impaired expression and regulation of genes and the appearance of proteins with altered functional properties. The corresponding germinogenic mutations alter the structure of the enzymes metabolizing medicines and transporting them, which affect the efficiency of medicine use. Knowledge of these mutations provides a rationale for individualized treatment [4, 5].

In this regard, much attention is paid to the role of SNPs in the development and progression of breast cancer, as well as their role in diagnosing and predicting the course of the disease.

The increasing interest of the role of SNP in the development and progression of breast cancer is confirmed by the number of studies and publications in the study of SNP in patients with breast cancer, but there are no clear recommendations on the application of these results.

**Materials and methods.** A literature review was conducted in electronic databases included in PubMed/Medline, The Cochrane Library. The depth of search was 10 years. The following search terms were used for the search: breast cancer, single nucleotide polymorphism, prognosis of the course, risk of development. Received 3192 publications on the requested terms.

**Results and discussion.** Environmental factors and metabolic disorders are the main causes of DNA damage [6].

Excision repair is one of the ways to restore DNA, when an exact enzymatic replacement of damaged or altered bases on one strand of the damaged two-stranded DNA molecule. Mutations that occur in related genes can lead to changes in the functions of recovery, and then significantly increase the likelihood of developing malignant tumors [7].

A number of researchers have studied the association between susceptibility to breast cancer and single SNPs in the excision repair genes. In these studies, human apurinic/apyrimidinic endonuclease (APE1), X-ray repair cross-complementing protein 1 (XRCC1), 8-oxoguanine DNA glycosylase (OGG1, also known as hOGG1) and poly (ADP-ribose) polymerase-1 (ADPAT1, also known as PARP1) were studied. Among these polymorphisms studied, the association was found between the risk of developing breast cancer and the rs25487 and rs1799782 mutations in the XRCC1 gene. A positive association between the rs25487 mutation [8–11] and the risk of breast cancer was registered in the study of one race, and was not obtained in the study of other races [12]. Most studies have shown that the rs1799782 mutation is not associated with the development of breast cancer, while in other studies, a positive correlation has been obtained [8 - 12]. Contradictory results were also presented in papers that explored populations consisting of mixed races. In 2001, Duell et al. (2001) reported that a positive association for rs25487 with breast cancer was found among African Americans, but not Caucasian Americans [13]. Vieira et al. (2015) demonstrates that the genetic background can influence the development of breast cancer and even has a reverse association [14].

A clinical study of NSABP B-31, in conjunction with the study of NCCTG N9831, established the advantage of adding trastuzumab, a monoclonal antibody targeting ERBB2/HER2 protein, to standard chemotherapy in patients with early-stage ERBB2/HER2-positive breast cancer. However, only 30 to 50% of patients use this therapy in early or adjuvant conditions [15]. Although this treatment is generally well tolerated, its cost and cardiotoxic effects and the availability of promising alternatives require research aimed at identifying patients who will not benefit from this treatment.

In the original patent of trastuzumab, two mechanisms of action are described.

First, by binding to ERBB2/HER2 on the cancer cell membrane, it prevents the dimerization of ERBB2/HER2, blocking the signaling pathway and proliferation. Secondly, it triggers the host immune system to attack and destroy the trastuzumab-associated tumor cells. This immune response, known as antibody-dependent cell-mediated cytotoxic effect (ADCC), is initiated when the FC $\gamma$  receptor on natural killer cells (NK) binds to the Fc portion of trastuzumab. As a result, NK cells secrete factors, including IFN- $\gamma$ , perforins and granzymes, which cause tumor cell death through the mechanism of apoptosis. A similar process, known as antibody-dependent cellular phagocytosis (ADCP).

In studies on ERBB2/HER2 breast cancer cell lines, we demonstrated potent ADCC caused by trastuzumab in vitro. Experiments in mice demonstrated a decrease in the efficacy of trastuzumab if the Fc fragment is removed from the antibody or if the mouse lacks the FC $\gamma$  receptor. In addition, an increase in lymphoid cell infiltration in tumor samples was observed after treatment with trastuzumab compared with samples after neoadjuvant treatment. Taken together, these results confirm the important role of ADCC or ADCP in the mechanism of action of trastuzumab.

Additional preclinical studies have demonstrated the association of SNPs in genes encoding FC $\gamma$  receptors with the strength of the immune response. Many studies have focused on the position 158 FCGR3A, which encodes valine or phenylalanine and the position 131 FCGR2A, which encodes histidine or arginine [16, 17]. In vitro ADCC assays demonstrated a large trastuzumab-mediated ADCC with the Val VGR (V)/V genotype and a tendency to associate with the histidine (H)/H genotype FCGR2A-131

[16]. Analysis of peripheral blood mononuclear cells (PBMCs), after neoadjuvant and adjuvant therapy, demonstrated more differentiated changes in gene expression in patients with V/V or H/H genotypes than in patients with phenylalanine (F)/F or arginine (R)/R genotypes, which indicates a difference in the molecular response to trastuzumab according to genotype [17]. These observations are consistent with the data that FCγRIIA-131H and FCγRIIA-158V have a higher affinity for immunoglobulin (IgG) than proteins encoded by alternative alleles. Cells containing high affinity alleles more effectively mediate ADCC [18].

Clinical studies using therapeutic monoclonal antibodies, such as rituximab for the treatment of lymphoma and cetuximab for the treatment of colon cancer, have shown the association between the genotypes FCGR3A and FCGR2A with the effectiveness of treatment. However, clinical studies that study the association of these SNPs with the effect of trastuzumab for patients with breast cancer are not unambiguous. Tamura et al. [19] demonstrated improved response rates to trastuzumab in patients with the FCGR2A -131 H/H genotype in the neoadjuvant mode and an increase in the frequency of the objective response in the treatment of the metastatic process. Musolino A. and his colleagues [20] observed an improvement in the objective response and an increase in progression-free survival for patients with the FCGR3A -158 V/V genotype. However, when analyzing the results of the study of patients included in NCCTG-N9831 [21] and BCIRG-006 [22], no association of these loci with the efficacy of trastuzumab in the adjuvant treatment of ERBB2/HER2-positive breast cancer was found.

Fluoropyrimidines are the most common and effective chemotherapeutic agents used for the systemic treatment of various malignant tumors, including the gastrointestinal tract, breast, pancreas, head and neck cancers [23 - 25].

DPD (dihydropyrimidine dehydrogenase), encoded by the DPYD gene, is the initial and rate-limiting enzyme in the metabolic pathway of fluoropyrimidines, such as 5-Fu, capecitabine and tegafur.

The clinical significance of DPD was initially determined in connection with severe or lethal toxicity in patients receiving fluoropyrimidines who did not have or had low levels of DPD activity [26]. More than 50 DPYD polymorphisms that cause fluoropyrimidine - associated toxicity in the treatment of malignant tumors, such as breast cancer, colon carcinomas, gastroesophageal cancer and lymphoblastic leukemia have been identified [27-30].

According to a number of authors, DPYD polymorphisms can contribute to tumor progression and affect sensitivity to chemotherapy, as well as the clinical outcome of cancer patients. DPYD SNPs have been reported to lead to an increased risk of developing ovarian and gastrointestinal cancers with the DPYD genotype c.1627A> G AG / GG, resulting in low sensitivity to fluorouracil-based adjuvant therapy [29-31]. However, the prognostic value of DPYD polymorphisms in breast cancer has been little studied. Fengxia Qin et al. in their work considered the association between SNP DPYD and the effect of therapy based on regimens containing taxanes and anthracyclines (TA) [32]. The authors found that patients with non-wild type DPYD carriers treated with the TA regimen had a longer overall survival compared with "wild type" carriers who did not receive this treatment regimen.

To date, more than 160 polymorphisms have been identified in the DPYD gene, but the number of publications on their study in Asian patients with breast cancer is very limited [33]. DPYD genetic polymorphisms can provide direct, valuable prognostic information. It is possible that for patients with breast cancer with the presence of DPYD c.1627A> G AG/GG polymorphism, chemotherapy based on fluoropyrimidines is not recommended for use.

**Conclusion.** The determination of SNPs can reveal a hereditary predisposition to various multifactorial diseases (including cancer), as well as predict individual sensitivity to pharmacological medicines. Considering the presence of numerous studies suggesting the possibility of developing personalized approaches in the management of breast cancer using the assessment of SNP mutations, further research is needed in individual populations. Applying this strategy can help physicians choose the most effective treatment for breast cancer patients.

**Conflict of interest.** The authors declare no conflict of interest.

**Funding.** The study was conducted as part of the implementation of the scientific and technical program "New molecular genetic methods of pre-symptom diagnosis and treatment methods for a number of significant diseases" funded by the Ministry of Health of the Republic of Kazakhstan.



**В. В. Бенберин<sup>1</sup>, Н. А. Шаназаров<sup>1</sup>, Н. К. Сейдалин<sup>1</sup>,  
Н. Ю. Лисовская<sup>2</sup>, Т. А. Вощенкова<sup>1</sup>, Г. А. Ермаханова<sup>1</sup>**

<sup>1</sup>Қазақстан Республикасы Президенті Іс Басқармасы Медициналық орталығы Ауруханасы,  
Астана, Қазақстан,

<sup>2</sup>«Спиженко Клиникасы» онкология орталығы, Киев облысы, Украина

### **СҮТ БЕЗІ ҚАТЕРЛІ ІСІГІ БАР НАУҚАСТАРДА БІР НУКЛЕОТИДТІ ПОЛИМОРФИЗМДІ АНЫҚТАУДЫҢ КЛИНИКАЛЫҚ МАҢЫЗДЫЛЫҒЫ (ӘДЕБИ ШОЛУ)**

**Аннотация.** Мақсаты: Сүт безі обырының болжамы, ағымы, даму қаупімен ДНК-де нуклеотидтерді ауыстыруға қатысты әдебиеттегі деректерді зерделеу.

Материалдар мен әдістер. PubMed/Medline, Кокран кітапханасына кіретін электрондық дерекқорларында әдебиетке шолу жасалды. Әдебиеттерді іздеу тереңдігі 10 жыл болды.

Нәтижесі. Жеке популяцияларда сүт безі обыры кезінде емдеуге жауап беру, болжам мен ағымы, дамуындағы бір нуклеотидтік полиморфизмдердің ролі туралы деректер зерделенді. Зерттеу нәтижелері, ДНК-дегі нуклеотидтерді ауыстыру дәрілік препараттар әсерінің тиімділігі, аурудың дамуына шалдығушылықтың түрлілігі негізінде жатқанынан хабар береді.

Қорытынды. Бір нуклеотидтік полиморфизмдер түрлі мультифакторлық ауруларға тұқым қуалаудан болатын бейімділікті (оның ішінде онкологиялық) анықтайды, сонымен бірге фармакологиялық препараттарға жеке сезімталдықты болжамдайды. Бұл дәрігерлерге сүт безі обырымен ауыратын науқастарға анағұрлым тиімді емді таңдауға көмектеседі.

**Түйін сөздер:** сүт безі обыры, бір нуклеотидті полиморфизм, ағымды болжау, даму қаупі.

**В. В. Бенберин<sup>1</sup>, Н. А. Шаназаров<sup>1</sup>, Н. К. Сейдалин<sup>1</sup>,  
Н. Ю. Лисовская<sup>2</sup>, Т. А. Вощенкова<sup>1</sup>, Г. А. Ермаханова<sup>1</sup>**

<sup>1</sup>Больница Медицинского центра Управления делами Президента Республики Казахстан,  
Астана, Казахстан,

<sup>2</sup>Центр онкологии «Клиника Спиженко», Киевская область, Украина

### **КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ ОПРЕДЕЛЕНИЯ ОДНОНУКЛЕОТИДНЫХ ПОЛИМОРФИЗМОВ У БОЛЬНЫХ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ (ОБЗОР ЛИТЕРАТУРЫ)**

**Аннотация.** Цель обзора: Изучение данных литературы касающихся замены нуклеотидов в ДНК с риском развития, течения и прогноза рака молочной железы.

Материалы и методы. Проведен поиск литературы в электронных базах данных, вошедших в PubMed/Medline, The Cochrane Library. Глубина поиска составляла 10 лет.

Результаты. Изучены данные о роли однонуклеотидных полиморфизмов в развитии, течении, прогнозе и ответе на лечение при раке молочной железы в отдельных популяциях. Результаты исследований свидетельствуют, что замена нуклеотидов в ДНК, лежит в основе различий восприимчивости к развитию заболеваний, эффективности действия лекарственных препаратов.

Заключение. Определение однонуклеотидных полиморфизмов может выявить наследственную предрасположенность к различным мультифакторным заболеваниям (в том числе и онкологическим), а также прогнозировать индивидуальную чувствительность к фармакологическим препаратам. Это может помочь врачам, выбрать наиболее эффективное лечение для больных раком молочной железы.

**Ключевые слова:** рак молочной железы, однонуклеотидные полиморфизмы, прогноз течения, риск развития.

#### **Information about authors:**

Benberin V. V., doctor of medical sciences, professor, corresponding member of the National Academy of Sciences of Kazakhstan, director of the Medical Center Hospital of the President's Affairs Administration of the Republic of Kazakhstan, Astana, Kazakhstan; valeriy-benberin@mail.ru; <https://orcid.org/0000-0002-7286-1593>

Shanazarov N. A., doctor of medical sciences, deputy director for science of the Medical Center Hospital of the President's Affairs Administration of the Republic of Kazakhstan, Astana, Kazakhstan; nasrulla@inbox.ru; <https://orcid.org/0000-0002-2976-259X>

Seidalin N. K., candidate of medical sciences, oncologist, specialist of the science department, Medical Center Hospital of the President's Affairs Administration of the Republic of Kazakhstan, Astana, Kazakhstan; nkseidalin@mail.ru, <https://orcid.org/0000-0003-3491-7354>

Lisovska N. Y., candidate of medical sciences, head of the department of chemotherapy, Center of Oncology 'Clinic of Spizhenko', Kiev region, Ukraine; lisovska67@gmail.com; <https://orcid.org/0000-0001-6114-708X>

Voshchenkova T. A., Master of Business Administration, deputy head of the Gerontology Center, Medical Center Hospital of the President's Affairs Administration of the Republic of Kazakhstan, Astana, Kazakhstan; voshchenkova@gmail.com; <https://orcid.org/0000-0003-0935-6217>

Yermakhanova G. A., master of public health, head of Clinical trials Sector of the Center for Gerontology, Medical Center Hospital of the President's Affairs Administration of the Republic of Kazakhstan, Astana, Kazakhstan; ermakhanova@gmail.com; <https://orcid.org/0000-0002-3542-4087>

## REFERENCES

[1] McGuire A., Brown J.A., Malone C., McLaughlin R., Kerin M.J. Effects of age on the detection and management of breast cancer // *Cancers (Basel)*. 2015. 7: 908-929.

[2] Anothaisintawee T., Wiratkapun C., Lertsitthichai P., Kasamesup V., Wongwaisayawan S., Srinakarin J., Hirunpat S., Woodtichartpreecha P., Boonlikit S., Teerawattananon Y., Thakkinstian A. Risk factors of breast cancer: a systematic review and meta-analysis // *Asia Pac J Public Health*. 2013. 25: 368-387.

[3] Colditz G.A., Kaphingst K.A., Hankinson S.E., Rosner B. Family history and risk of breast cancer: nurses' health study // *Breast Cancer Res Treat*. 2012. 133: 1097-1104.

[4] Schmidt K.T., Chau C.H., Price D.K., Figg W.D. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment // *J Clin Pharmacol*. 2016. 56: 1484-99.

[5] Benberin B.B., Vochshenkova T.A., Yermakhanova G.A., et al. (2018) Metabolic syndrome and cerebral stroke in Kazakhstan: some management factors // *Bulletin of National academy of sciences of the Republic of Kazakhstan*. 2018. Vol. 5, N 375. P. 55-59. ISSN 2518-1467 (Online), ISSN 1991-3494 (Print). <https://doi.org/10.32014/2018.2518-1467.7>

[6] Shevtsov M.A., Nikolaev B.P., Ryzhov V.A., Yakovleva L.Y., Marchenko Y.Y., Parr M.A., Rolich V.I., Mikhrina A.L., Dobrodumov A.V., Pitkin E., Multhoff G. Ionizing radiation improves glioma-specific targeting of superparamagnetic iron oxide nanoparticles conjugated with cmHsp70.1 monoclonal antibodies (SPION-cmHsp70.1) // *Nanoscale*. 2015 Dec 28. 7(48): 20652-64.

[7] Zhu G., Wang L., Guo H., Lu L., Yang S., Wang T., Guo H., Wang H., Min J., Yang K., Chen X., Liu Y., Wang Z., Su H. DNA repair genes XRCC1 and ERCC1 polymorphisms and the risk of sporadic breast cancer in Han women in the Gansu Province of China // *Genet Test Mol Biomarkers*. 2015. 19: 387-393.

[8] Shadrina A.S., Ermolenko N.A., Boyarskikh U.A., Sinkina T.V., Lazarev A.F., Petrova V.D., Filipenko M.L. Polymorphisms in DNA repair genes and breast cancer risk in Russian population: a case-control study // *Clin Exp Med*. 2016. 16: 21-28.

[9] Ramadan R.A., Desouky L.M., Elnaggar M.A., Moaaz M., Elsharif A.M. Association of DNA Repair Genes XRCC1 (Arg399Gln), (Arg194Trp) and XRCC3 (Thr241Met) Polymorphisms with the Risk of Breast Cancer: A Case-Control Study in Egypt // *Genet Test Mol Biomarkers*. 2014. 18: 754-760.

[10] Ding P., Yang Y., Cheng L., Zhang X., Cheng L., Li C., Cai J. The relationship between seven common polymorphisms from five DNA repair genes and the risk for breast cancer in northern Chinese women // *PLoS One*. 2014. 9: e92083.

[11] Luo H., Li Z., Qing Y., Zhang S.H., Peng Y., Li Q., Wang D. Single nucleotide polymorphisms of DNA base-excision repair genes (APE1, OGG1 and XRCC1) associated with breast cancer risk in a Chinese population // *Asian Pac J Cancer Prev*. 2014. 15: 1133-1140.

[12] Al Zoubi M.S. X-ray repair cross-complementing protein 1 and 3 polymorphisms and susceptibility of breast cancer in a Jordanian population // *Saudi Med J*. 2015. 36: 1163-1167.

[13] Duell E.J., Millikan R.C., Pittman G.S., Winkel S., Lunn R.M., Tse C.K., Eaton A., Mohrenweiser H.W., Newman B., Bell D.A. Polymorphisms in the DNA repair gene XRCC1 and breast cancer // *Cancer Epidemiol Biomarkers Prev*. 2001. 10: 217-222.

[14] Vieira P.C., Burbano R.M., Fernandes D.C., Montenegro R.C., Dos Santos S.E., Sortica V.A., Assumpcao P.P., Ribeiro-Dos-Santos A.K., Carvalho A.A., Dos Santos N.P. Population stratification effect on cancer susceptibility in an admixed population from Brazilian Amazon // *Anticancer Res*. 2015. 35: 2009-2014.

[15] Mellor J.D., Brown M.P., Irving H.R., Zalberg J.R., Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer // *J Hematol Oncol*. 2013. 6:1.

[16] Musolino A., Naldi N., Bortesi B., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer // *J Clin Oncol*. 2008. 26(11): 1789-1796.

[17] Shimizu C., Mogushi K., Morioka M.S., et al. Fc-Gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab // *Breast Cancer*. 2016. 23(4): 624-632.

[18] Mellor J.D., Brown M.P., Irving H.R., Zalberg J.R., Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer // *J Hematol Oncol*. 2013. 6:1.

[19] Tamura K., Shimizu C., Hojo T., et al. FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer // *Ann Oncol*. 2011. 22(6): 1302-1307.

[20] Musolino A., Naldi N., Bortesi B., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer // *J Clin Oncol*. 2008. 26(11): 1789-1796.

- [21] Norton N., Olson R.M., Pegram M., et al. Association studies of Fc $\gamma$  receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831 // *Cancer Immunol Res.* 2014. 2(10): 962-969.
- [22] Hurvitz S.A., Betting D.J., Stern H.M., et al. Analysis of Fc $\gamma$  receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients // *Clin Cancer Res.* 2012. 18(12): 3478-3486.
- [23] Tecza K., Pamula-Pilat J., Lanuszewska J., Grzybowska E. Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients // *Oncotarget.* 2016. 7: 66790-808.
- [24] Patel K., Yerram S.R., Azad N.A., Kern S.E. A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing // *Oncotarget.* 2012. 3: 678-85.
- [25] Del Re M., Quaquareni E., Sottotetti F., Michelucci A., Palumbo R., Simi P., Danesi R., Bernardo A. Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant // *Pharmacogenomics.* 2016. 17: 5-9.
- [26] Offer S.M., Wegner N.J., Fossum C., Wang K., Diasio R.B. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity // *Cancer Res.* 2013. 73: 1958-68.
- [27] Zhao X.Q., Cao W.J., Yang H.P., Yang X.W., Tang P., Sun L., Gao X. DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia // *Tumour Biol.* 2016. 37: 10393-402.
- [28] Saif M.W. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD // *Cancer Genomics Proteomics.* 2013. 10:89-92.
- [29] Joerger M., Huitema A.D., Boot H., Cats A., Doodeman V.D., Smits P.H., Vainchtein L., Rosing H., Meijerman I., Zueger M., Meulendijks D., Cerny T.D., Beijnen J.H., et al. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy // *Cancer Chemother Pharmacol.* 2015. 75: 763-72.
- [30] Kelemen L.E., Terry K.L., Goodman M.T., Webb P.M., Bandera E.V., McGuire V., Rossing M.A., Wang Q., Dicks E., Tyrer J.P., Song H., Kupryjanczyk J., Dansonka-Mieszkowska A., et al. Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk // *Mol Nutr Food Res.* 2014. 58: 2023-35.
- [31] Zhang X.P., Bai Z.B., Chen B.A., Feng J.F., Yan F., Jiang Z., Zhong Y.J., Wu J.Z., Chen L., Lu Z.H., Tong N., Zhang Z.D., Xu P.P., et al. Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population // *Chin Med J (Engl)* 2012. 125: 741-6.
- [32] Fengxia Qin, Huikun Zhang, Yong Huang, Limin Yang, Feng Yu, Xiaoli Liu, Li Fu, Feng Gu, Yongjie Ma. Effect of dihydropyrimidine dehydrogenase single nucleotide polymorphisms on prognosis of breast cancer patients with chemotherapy // *Oncotarget.* 2017 Dec 19. 8(67): 112060-112075.
- [33] Toffoli G., Giodini L., Buonadonna A., Berretta M., De Paoli A., Scalone S., Miolo G., Mini E., Nobili S., Lonardi S., Pella N., Lo Re G., Montico M., et al. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines // *Int J Cancer.* 2015. 137: 2971-80.

---

---

**Publication Ethics and Publication Malpractice  
in the journals of the National Academy of Sciences of the Republic of Kazakhstan**

For information on Ethics in publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/journal-authors/ethics>.

Submission of an article to the National Academy of Sciences of the Republic of Kazakhstan implies that the described work has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. In particular, translations into English of papers already published in another language are not accepted.

No other forms of scientific misconduct are allowed, such as plagiarism, falsification, fraudulent data, incorrect interpretation of other works, incorrect citations, etc. The National Academy of Sciences of the Republic of Kazakhstan follows the Code of Conduct of the Committee on Publication Ethics (COPE), and follows the COPE Flowcharts for Resolving Cases of Suspected Misconduct ([http://publicationethics.org/files/u2/New\\_Code.pdf](http://publicationethics.org/files/u2/New_Code.pdf)). To verify originality, your article may be checked by the Cross Check originality detection service <http://www.elsevier.com/editors/plagdetect>.

The authors are obliged to participate in peer review process and be ready to provide corrections, clarifications, retractions and apologies when needed. All authors of a paper should have significantly contributed to the research.

The reviewers should provide objective judgments and should point out relevant published works which are not yet cited. Reviewed articles should be treated confidentially. The reviewers will be chosen in such a way that there is no conflict of interests with respect to the research, the authors and/or the research funders.

The editors have complete responsibility and authority to reject or accept a paper, and they will only accept a paper when reasonably certain. They will preserve anonymity of reviewers and promote publication of corrections, clarifications, retractions and apologies when needed. The acceptance of a paper automatically implies the copyright transfer to the National Academy of Sciences of the Republic of Kazakhstan.

The Editorial Board of the National Academy of Sciences of the Republic of Kazakhstan will monitor and safeguard publishing ethics.

Правила оформления статьи для публикации в журнале смотреть на сайте:

[www:nauka-nanrk.kz](http://www.nauka-nanrk.kz)

**ISSN 2518-1467 (Online), ISSN 1991-3494 (Print)**

<http://www.bulletin-science.kz/index.php/en/>

Редакторы *М. С. Ахметова, Т. М. Апендиев, Д. С. Аленов*  
Верстка на компьютере *Д. Н. Калкабековой*

Подписано в печать 10.10.2019.  
Формат 60x881/8. Бумага офсетная. Печать – ризограф.  
13,9 п.л. Тираж 500. Заказ 5.